SARS-CoV-2: Difference between revisions
From IDWiki
m (Text replacement - "Clinical Presentation" to "Clinical Manifestations") |
No edit summary |
||
Line 1: | Line 1: | ||
== |
==Background== |
||
=== |
===Microbiology=== |
||
⚫ | |||
⚫ | |||
⚫ | |||
*Virion consists of: |
|||
⚫ | |||
**Spike glycoprotein (S) |
|||
* Declared pandemic by WHO in 2020 |
|||
**Membrane protein (M) |
|||
**Nucleocapsid protein (N) |
|||
**Hemagglutinin esterase (He) |
|||
**Envelope protein (E) |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
*Secondary household attack rate of 12-17% |
|||
* Primarily supportive |
|||
⚫ | |||
=== Risk Factors for Mortality === |
|||
* Greater age |
|||
* Male sex |
|||
* [[COPD]] |
|||
* [[Dyslipidemia]] |
|||
* [[Diabetes]] |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
*Lymphopenia is common, as is hypoalbuminemia, elevated D-dimer, CRP, LDH, AST/ALT |
|||
*Viral load detectable before symptom onset and peaks around the time of symptom onset |
|||
=== Complications === |
|||
* In critically ill patients: |
|||
** [[ARDS]] (75%) |
|||
** [[AKI]] (40%) |
|||
** [[Thrombosis]] (10%) |
|||
== Diagnosis == |
|||
* PCR from NP swab |
|||
** May be positive long after no longer infectious |
|||
⚫ | |||
*Dexamethasone for patients requiring supplemental oxygen |
|||
⚫ | |||
== Further Reading == |
|||
* 10.1001/jama.2020.12839 |
|||
[[Category:Viruses]] |
[[Category:Viruses]] |
Revision as of 23:16, 30 July 2020
Background
Microbiology
- Coronavirus related to SARS-CoV
- Virion consists of:
- Spike glycoprotein (S)
- Membrane protein (M)
- Nucleocapsid protein (N)
- Hemagglutinin esterase (He)
- Envelope protein (E)
Epidemiology
- First cases detected Dec 2019 related to likely exposure in wet market in Wuhan, Hubei, China, and declared a pandemic in 2020
- Secondary household attack rate of 12-17%
Risk Factors for Mortality
- Greater age
- Male sex
- COPD
- Dyslipidemia
- Diabetes
Clinical Manifestations
- Incubation period 4-5 days (range 2 to 11), possibly as long as 14 days in some cases
- Main presenting symptoms were fever and cough, followed by myalgia, fatigue, headache, dyspnea
- Other symptoms include dyspnea, rhinorrhea, vomiting, diarrhea, anosmia/hyposmia
- Lymphopenia is common, as is hypoalbuminemia, elevated D-dimer, CRP, LDH, AST/ALT
- Viral load detectable before symptom onset and peaks around the time of symptom onset
Complications
- In critically ill patients:
- ARDS (75%)
- AKI (40%)
- Thrombosis (10%)
Diagnosis
- PCR from NP swab
- May be positive long after no longer infectious
Management
- Dexamethasone for patients requiring supplemental oxygen
- Investigational therapeutics include tocilizumab, lopinavir/ritonavir, and chloroquine
Further Reading
- 10.1001/jama.2020.12839
References
- ^ Louise Lansbury, Benjamin Lim, Vadsala Baskaran, Wei Shen Lim. Co-infections in people with COVID-19: a systematic review and meta-analysis. Journal of Infection. 2020;81(2):266-275. doi:10.1016/j.jinf.2020.05.046.